Janux Therapeutics (NASDAQ:JANX) Raised to “Hold” at Wall Street Zen

Janux Therapeutics (NASDAQ:JANX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

JANX has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a report on Thursday, January 22nd. Barclays lowered their target price on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Cantor Fitzgerald cut their price objective on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Clear Str cut shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Finally, Piper Sandler reduced their target price on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Price Performance

JANX stock opened at $14.84 on Friday. The stock has a market capitalization of $902.72 million, a P/E ratio of -8.11 and a beta of 2.82. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The business has a 50-day moving average of $13.70 and a 200-day moving average of $18.95.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $0.08 million. Equities analysts expect that Janux Therapeutics will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System boosted its stake in Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the last quarter. Nuveen LLC raised its position in Janux Therapeutics by 0.8% in the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after buying an additional 787 shares during the last quarter. Congress Asset Management Co. lifted its stake in Janux Therapeutics by 2.8% during the 4th quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock valued at $791,000 after acquiring an additional 1,569 shares during the period. ProShare Advisors LLC lifted its stake in Janux Therapeutics by 18.3% during the 4th quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after acquiring an additional 1,621 shares during the period. Finally, Kennedy Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 20.0% during the 3rd quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after acquiring an additional 1,905 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.